Form 8-K AbCellera Biologics Inc. For: Jun 11
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 11, 2026
__________________________________________
(Exact name of registrant as specified in its charter)
__________________________________________
| Not Applicable | ||||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||
150 W 4th Avenue | |||||
| (Address of registrant’s principal executive office) | (Zip code) | ||||
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07 Submission of Matters to a Vote of Security Holders.
AbCellera Biologics Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 305,264,947 common shares of the Company outstanding and entitled to vote at the Annual Meeting. The Company’s shareholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2026: (i) to elect John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors of the Company to serve for a three-year term expiring at the Company’s annual meeting of shareholders in 2029 and until his or her successor has been elected and qualified (“Proposal 1”), (ii) to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”), and (iii) to approve on a non-binding advisory basis, the compensation of the Company’s named executive offices, or Say-on-Pay (“Proposal 3”).
Proposal 1
The Company’s shareholders approved the election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors recommended for election in Proposal 1 at the Annual Meeting. The Company’s shareholders voted for the Class III directors as follows:
| Nominee | For | Against | Abstain | ||||||||
| John S. Montalbano, CFA | 141,430,732 | 12,723,342 | 45,898 | ||||||||
| Stephen R. Quake, D.Phil. | 149,019,960 | 5,113,056 | 66,956 | ||||||||
The broker non-votes for this Proposal 1 totaled 36,576,359 common shares.
Proposal 2
The Company’s shareholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:
| For | Against | Abstain | ||||||
| 189,927,972 | 552,429 | 295,930 | ||||||
Proposal 3
The Company’s shareholders approved Proposal 3. The votes cast at the Annual Meeting were as follows:
| For | Against | Abstain | ||||||
| 142,831,950 | 10,932,105 | 435,917 | ||||||
The broker non-votes for this Proposal 3 totaled 36,576,359 common shares.
No other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 12, 2026 | ABCELLERA BIOLOGICS INC. | |||||||
| By: | /s/ Carl L. G. Hansen | |||||||
| Carl L. G. Hansen, Ph.D. | ||||||||
Chief Executive Officer and Director (Principal Executive Officer) | ||||||||
ATTACHMENTS / EXHIBITS
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals and AbCellera ink antibody research deal
- MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
- 3D AI Studio Launches Flow: Node-Based 3D Workflows That Run in the Browser With No GPU or Setup
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
